Table 2.
Clinical characteristics and their correlation with myocardial T1 values
| Mean±SD, median (IQR) or n (%) | r | P value | |
| General information | |||
| Age at onset, years old | 41.0±14.3 | −0.077 | 0.616 |
| Years since diagnosis | 5.36 (3.0–9.1) | −0.019 | 0.902 |
| Sex, male | 5 (11.1) | −1.74 | 0.252 |
| BMI, kg/m2 | 22.6±3.8 | −0.183 | 0.177 |
| Diabetes | 4 (8.9) | 0.165 | 0.278 |
| Hypertension | 6 (13.3) | −0.103 | 0.500 |
| Smoking | 2 (4.4) | −0.032 | 0.832 |
| Subset (dcSSc) | 23 (51.1) | −0.161 | 0.291 |
| Modified Rodnan skin score | 2 (1–6) | −0.042 | 0.783 |
| Manifestations | |||
| Raynaud’s phenomenon | 42 (93.3) | 0.165 | 0.280 |
| Myositis | 6 (13.3) | 0.199 | 0.190 |
| Arthritis/arthralgia | 10 (22.2) | 0.239 | 0.114 |
| Digital ulcers | 12 (26.7) | −0.006 | 0.970 |
| ILD | 28 (62.2) | 0.028 | 0.854 |
| PAH | 1 (2.2) | −0.012 | 0.940 |
| LV diastolic dysfunction | 13 (28.9) | 0.021 | 0.892 |
| Scleroderma renal crisis | 2 (4.4) | 0.199 | 0.189 |
| Leucopenia | 4 (8.9) | −0.120 | 0.504 |
| Thrombocytopaenia | 3 (6.7) | 0.130 | 0.393 |
| Laboratory test | |||
| eGFR (mL/min) | 105±27.6 | −0.001 | 0.996 |
| Anti-SCL70 antibody positivity | 17 (37.8) | −0.152 | 0.320 |
| ACA positivity | 4 (8.9) | 0.084 | 0.582 |
| Evaluated BNP or NT-proBNP | 12 (26.7) | −0.072 | 0.640 |
| Evaluated CTnI | 1 (2.2) | 0.197 | 0.194 |
anti-Scl 70, anti-topoisomerase I antibodies; ACA, anticentromere antibody; BMI, body mass index; BNP, brain natriuretic peptide; CTnI, cardiac troponin I; dcSSc, diffuse cutaneous SSc; eGFR, estimated glomerular filtration rate; ILD, interstitial lung disease; LV, left ventricle; NT-proBNP, pro-hormone BNP; PAH, pulmonary arterial hypertension; SSc, systemic sclerosis.